Acute Coronary SyndromeSACS ScoreNCT00947804
Study to Validate Simple Acute Coronary Syndrome Score
An observational study of Acute Coronary Syndrome, run by St. Joseph's Hospital, Florida at 1 site in United States.
Trial summary
The Simple Acute Coronary Syndrome (SACS) Score was developed as a Risk Stratification Tool for Acute Coronary Syndrome (ACS). It is a tool which rates a patient's: SYMPTOMS, EKG FINDINGS, RISK FACTOR PROFILE, and CARDIAC MARKERS on a scale of zero to six. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Acute Coronary Syndrome
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- Aug 2009to Jun 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult patients presenting to the cardiac catherization suite whom have experienced ACS symptoms within the past thirty days.
Who may be able to join
- Must be mentally competent with ability to articulate symptoms and risk factor profile
Who cannot join
- Renal disease
- When unable to obtain all required data sets (SYMPTOMS, EKG, TIMI RISK FACTOR PROFILES, CARDIAC LABS)
- EKG displays DELTA WAVES consistent with Wolff-Parkinson-White Syndrome
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Phase 1 - Pilot Study to Validate the Simple Acute Coronary Syndrome Score; an Acute Coronary Syndrome (ACS) Risk Stratification Tool
The Simple Acute Coronary Syndrome (SACS) Score was developed as a Risk Stratification Tool for Acute Coronary Syndrome (ACS). It is a tool which rates a patient's: SYMPTOMS, EKG FINDINGS, RISK FACTOR PROFILE, and CARDIAC MARKERS on a scale of zero to six.
The purpose of this study is to validate the SACS Scoring tool by establishing a correlation between the score's numerical values and the degree of obstructive cardiovascular disease visualized during cardiac catheterization.
Read the detailed description
Depending on whose published research is referenced, an estimated 68,000 to 136,000 people with ACS are misdiagnosed and discharged annually from our nation's emergency departments. The emotional loss to grieving family members is incalculable. The negative financial impact to families who lose their primary income providers and losses incurred by health care providers in legal expenses is also significant. Misdiagnosis of ACS is due, in part, to:
- Patients presenting with ATYPICAL symptoms of ACS
- Problems with SENSITIVITY and SPECIFICITY with the 12 Lead EKG
- Inconsistent integration of Patients' Coronary Artery Disease (CAD) Risk Factor Profile into the clinical decision making process.
One solution to improving ACS diagnostic accuracy is for clinicians to utilize an ACS Risk Stratification Tool that is proven to be highly sensitive and specific with respect to identifying patients with significant underlying CAD.
While screening approximately 50 patient case studies for inclusion in a 12 Lead EKG education curriculum, multiple incidents were noted where the patient's Modified TIMI ACS Risk Score did not accurately correlate with the patient's degree of cardiovascular disease. In several cases, the disparity between the Modified TIMI Risk Score and the patient's disease status was so great that if clinicians had considered this score in the clinical decision making process, patients would have been discharged with "clean bills of health," while actually having severe underlying CAD; scenarios that would have "set the stage" for adverse outcomes.
In the search for a more reliable ACS Risk Stratification Tool, none were found that were deemed consistently reliable enough for use as an adjunct to clinical decision making. This could be due, in part, to the fact that the tools currently available (TIMI, GRACE, PURSUIT), were primarily designed as prognostic indicators of mortality in patients diagnosed with ST Segment Elevation Myocardial Infarction (STEMI) in pharmaceutical studies - not as tools to assess the probability that ACS exists in patients presenting to the Emergency Department. This prompted the development of the SACS Score.
In approximately 50 cases informally studied to date, the SACS scoring tool produced scores that are more consistent and more predictive of the presence of obstructive CAD than the Modified TIMI Risk Score.
Our formal study will consist of at least 200 patients, which will include two groups.
GROUP 1 will consist of all Acute Myocardial Infarction (AMI) patients (STEMI / NSTEMI) treated at St. Joseph's Hospital, beginning in January, 2009 and continuing until our target number of 200 patients is obtained. In order to not delay urgent cardiac catheterization and treatment, these patients will be studied retrospectively (post cardiac catheterization and intervention).
GROUP 2 will consist of randomly selected patients whom are clinically stable at the time of cardiac catheterization. These patients will be studied prospectively. To maintain integrity of the study, these patients will be selected, with written consent obtained, prior to cardiac catheterization.
Data to be collected in all case studies (both groups) will include demographics and specific information about the patient's SYMPTOMS, EKG FINDINGS, RISK FACTOR PROFILE and CARDIAC LABS.
NOTE: ADDED JULY, 2010: To assure accuracy with respect to comparison of the SACS score to other ACS Risk Stratification scoring tools, we will only include patients in our study whose medical records reflect accurate risk factor history assessments which are consistent with TIMI risk factor assessment guidelines. For example, if it is recorded that the patient has "Family History Positive for Coronary Artery Disease," but it does not state specifically WHICH family member(s), and/or does not state the SPECIFIC CARDIAC DIAGNOSIS (such as "Acute Myocardial Infarction"), and/or does not include the AGE of the family member at the time of diagnosis, we WILL NOT include the patient in our study. A complete list of TIMI Risk Factor Assessment Guidelines TIMI guidelines can be found at www.TIMI.org,
POST CARDIAC CATHETERIZATION data will be classified into categories based on cath lab findings:
- No visible CAD present
- Mild-to-moderate plaquing without obstructive CAD. No catheter-based or surgical intervention was performed. Number of lesions, location(s), and percentage(s) of arterial obstruction will be specified.
- Significant obstructive CAD present. Number of lesions, location(s), and percentage(s) of arterial obstruction and intervention(s) performed will be specified.
- Acute total occlusion of coronary artery requiring emergency intervention. Location of lesion and intervention(s) performed will be specified.
Regression Analysis of 126 data points collected from each patient will be used to establish relationships between score values and the degree of obstructive CAD present.
We believe that once scientifically validated, the SACS Score will become a useful tool to aid medical professionals in reducing the incidence of patients whom are misdiagnosed with respect to ACS.
- Conditions
- Acute Coronary Syndrome
- Keywords
- Acute Coronary Artery Syndrome Risk Stratification Score
- Medical subject headings
- Acute Coronary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| 1. Patients with symptoms of ACS | Patients whom present emergently to the Cardiac Catheterization Lab with current symptoms of Acute Coronary Syndrome (ACS), whom at the time of admission to the cardiac catheterization lab are believed to be suffering from STEMI, NSTEMI, or Unstable Angina, with the possible need for emergency Percutaneous Coronary Intervention (PCI), or Coronary Artery Bypass Grafting (CABG). | |
| 2. Patients without symptoms of ACS | Non-emergency patients presenting to the Cardiac Catheterization Lab for elective coronary angiography, and possible PCI. These are patients whom may have experienced typical or atypical ACS symptoms intermittently, and have elected to have cardiac catheterization to rule out obstructive CAD. Patients in this group will be selected randomly, with consent obtained, prior to cardiac catheterization. |
What is being measured
The primary outcome is the main question the study is designed to answer.
PRESENCE or ABSENCE of obstructive CAD as discovered during non-investigative coronary angiography in the Cardiac Catheterization Lab.
Measured: Within 24 hours of: a) arrival in Emergency Department, or b) admission to the hospital
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2009 (estimated)
- Study startAug 2009
- Primary completionDec 2013 (estimated)
- Study completionJun 2014 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Coronary SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- St. Joseph's Hospital, Florida
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Wayne Ruppert, St. Joseph's Hospital, Florida
- Investigators
- Wayne W Ruppert, CVT, Principal investigator, St. Joseph's Hospital, Tampa, FLHumberto Coto, MD, FACC, Study director, St. Joseph's Hostpial, Tampa, FloridaXavier E Prida, MD, FACC, Study director, St. Joseph's Hospital, Tampa, FloridaCharles Sand, MD, FACEP, Study director, St. Joesph's Hospital, Tampa, FL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00947804
- Sponsor's protocol ID
- ACS SACS Score SJH-01
- Acronym
- SACS Score
- Status last verified
- Dec 2012
- First submitted
- 26 Jul 2009
- Last updated
- 8 Apr 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 1 - Pilot Study to Validate the Simple Acute Coronary Syndrome Score; an Acute Coronary Syndrome (ACS) Risk Stratification Tool
- ClinicalTrials.gov ID
- NCT00947804
- Acronym / sponsor ID
- SACS Score / ACS SACS Score SJH-01
- Conditions
- Acute Coronary Syndrome
- Keywords
- Acute Coronary Artery Syndrome Risk Stratification Score
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- St. Joseph's Hospital, FloridaUniversity, hospital or other
- Study start
- Aug 2009
- Primary completion
- Dec 2013 (estimated)
- Study completion
- Jun 2014 (estimated)
- First posted
- 28 Jul 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Simple Acute Coronary Syndrome (SACS) Score was developed as a Risk Stratification Tool for Acute Coronary Syndrome (ACS). It is a tool which rates a patient's: SYMPTOMS, EKG FINDINGS, RISK FACTOR PROFILE, and CARDIAC MARKERS on a scale of zero to six.
The purpose of this study is to validate the SACS Scoring tool by establishing a correlation between the score's numerical values and the degree of obstructive cardiovascular disease visualized during cardiac catheterization.
Detailed description
Depending on whose published research is referenced, an estimated 68,000 to 136,000 people with ACS are misdiagnosed and discharged annually from our nation's emergency departments. The emotional loss to grieving family members is incalculable. The negative financial impact to families who lose their primary income providers and losses incurred by health care providers in legal expenses is also significant. Misdiagnosis of ACS is due, in part, to:
- Patients presenting with ATYPICAL symptoms of ACS
- Problems with SENSITIVITY and SPECIFICITY with the 12 Lead EKG
- Inconsistent integration of Patients' Coronary Artery Disease (CAD) Risk Factor Profile into the clinical decision making process.
One solution to improving ACS diagnostic accuracy is for clinicians to utilize an ACS Risk Stratification Tool that is proven to be highly sensitive and specific with respect to identifying patients with significant underlying CAD.
While screening approximately 50 patient case studies for inclusion in a 12 Lead EKG education curriculum, multiple incidents were noted where the patient's Modified TIMI ACS Risk Score did not accurately correlate with the patient's degree of cardiovascular disease. In several cases, the disparity between the Modified TIMI Risk Score and the patient's disease status was so great that if clinicians had considered this score in the clinical decision making process, patients would have been discharged with "clean bills of health," while actually having severe underlying CAD; scenarios that would have "set the stage" for adverse outcomes.
In the search for a more reliable ACS Risk Stratification Tool, none were found that were deemed consistently reliable enough for use as an adjunct to clinical decision making. This could be due, in part, to the fact that the tools currently available (TIMI, GRACE, PURSUIT), were primarily designed as prognostic indicators of mortality in patients diagnosed with ST Segment Elevation Myocardial Infarction (STEMI) in pharmaceutical studies - not as tools to assess the probability that ACS exists in patients presenting to the Emergency Department. This prompted the development of the SACS Score.
In approximately 50 cases informally studied to date, the SACS scoring tool produced scores that are more consistent and more predictive of the presence of obstructive CAD than the Modified TIMI Risk Score.
Our formal study will consist of at least 200 patients, which will include two groups.
GROUP 1 will consist of all Acute Myocardial Infarction (AMI) patients (STEMI / NSTEMI) treated at St. Joseph's Hospital, beginning in January, 2009 and continuing until our target number of 200 patients is obtained. In order to not delay urgent cardiac catheterization and treatment, these patients will be studied retrospectively (post cardiac catheterization and intervention).
GROUP 2 will consist of randomly selected patients whom are clinically stable at the time of cardiac catheterization. These patients will be studied prospectively. To maintain integrity of the study, these patients will be selected, with written consent obtained, prior to cardiac catheterization.
Data to be collected in all case studies (both groups) will include demographics and specific information about the patient's SYMPTOMS, EKG FINDINGS, RISK FACTOR PROFILE and CARDIAC LABS.
NOTE: ADDED JULY, 2010: To assure accuracy with respect to comparison of the SACS score to other ACS Risk Stratification scoring tools, we will only include patients in our study whose medical records reflect accurate risk factor history assessments which are consistent with TIMI risk factor assessment guidelines. For example, if it is recorded that the patient has "Family History Positive for Coronary Artery Disease," but it does not state specifically WHICH family member(s), and/or does not state the SPECIFIC CARDIAC DIAGNOSIS (such as "Acute Myocardial Infarction"), and/or does not include the AGE of the family member at the time of diagnosis, we WILL NOT include the patient in our study. A complete list of TIMI Risk Factor Assessment Guidelines TIMI guidelines can be found at www.TIMI.org,
POST CARDIAC CATHETERIZATION data will be classified into categories based on cath lab findings:
- No visible CAD present
- Mild-to-moderate plaquing without obstructive CAD. No catheter-based or surgical intervention was performed. Number of lesions, location(s), and percentage(s) of arterial obstruction will be specified.
- Significant obstructive CAD present. Number of lesions, location(s), and percentage(s) of arterial obstruction and intervention(s) performed will be specified.
- Acute total occlusion of coronary artery requiring emergency intervention. Location of lesion and intervention(s) performed will be specified.
Regression Analysis of 126 data points collected from each patient will be used to establish relationships between score values and the degree of obstructive CAD present.
We believe that once scientifically validated, the SACS Score will become a useful tool to aid medical professionals in reducing the incidence of patients whom are misdiagnosed with respect to ACS.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1. Patients with symptoms of ACS | – | –Patients whom present emergently to the Cardiac Catheterization Lab with current symptoms of Acute Coronary Syndrome (ACS), whom at the time of admission to the cardiac catheterization lab are believed to be suffering from STEMI, NSTEMI, or Unstable Angina, with the possible need for emergency Percutaneous Coronary Intervention (PCI), or Coronary Artery Bypass Grafting (CABG). |
| 2. Patients without symptoms of ACS | – | –Non-emergency patients presenting to the Cardiac Catheterization Lab for elective coronary angiography, and possible PCI. These are patients whom may have experienced typical or atypical ACS symptoms intermittently, and have elected to have cardiac catheterization to rule out obstructive CAD. Patients in this group will be selected randomly, with consent obtained, prior to cardiac catheterization. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients presenting to the cardiac catherization suite whom have experienced ACS symptoms within the past thirty days.
Key inclusion criteria (1 listed)
- Must be mentally competent with ability to articulate symptoms and risk factor profile
Key exclusion criteria (3 listed)
- Renal disease
- When unable to obtain all required data sets (SYMPTOMS, EKG, TIMI RISK FACTOR PROFILES, CARDIAC LABS)
- EKG displays DELTA WAVES consistent with Wolff-Parkinson-White Syndrome
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
PRESENCE or ABSENCE of obstructive CAD as discovered during non-investigative coronary angiography in the Cardiac Catheterization Lab.
Time frame: Within 24 hours of: a) arrival in Emergency Department, or b) admission to the hospital
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2013.
Related trials for Acute Coronary Syndrome
Recruiting
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
Coronary Arterial Disease (CAD), Plaque
RecruitingPhase 4
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome
ACS (Acute Coronary Syndrome), SGLT2 Inhibitors
Not yet recruitingPhase 3
Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS)
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
Ischemic Heart Disease, Ischemic Coronary Artery Disease
Not yet recruitingPhase 4
Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
Acute Coronary Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wayne W Ruppert, CVT principal investigator
St. Joseph's Hospital, Tampa, FL
Humberto Coto, MD, FACC study director
St. Joseph's Hostpial, Tampa, Florida
Xavier E Prida, MD, FACC study director
St. Joseph's Hospital, Tampa, Florida
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Coronary Syndrome, run by St. Joseph's Hospital, Florida at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PRESENCE or ABSENCE of obstructive CAD as discovered during non-investigative coronary angiography in the Cardiac Catheterization Lab. (time frame: Within 24 hours of: a) arrival in Emergency Department, or b) admission to the hospital). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2013.